日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Advances in multiple myeloma: key updates from the ASH 2025 meeting

多发性骨髓瘤研究进展:ASH 2025 会议的主要更新

Naing, Phyu Thin; Baljevic, Muhamed

Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: the Vanderbilt experience

在接受BCMA和GPRC5D双特异性抗体治疗的多发性骨髓瘤患者中,采用固定剂量静脉注射免疫球蛋白进行原发感染预防:范德比尔特大学的经验

Marneni, Naimisha; Lessans, Spencer; Dholaria, Bhagirathbhai; Sengsayadeth, Salyka; Biltibo, Eden A; Patel, Vivek; Bhaskar, Shakthi; Jayani, Reena; Mohan, Sanjay; Kishtagari, Ashwin; Morgan, David; Oluwole, Olalekan O; Savani, Bipin N; Kassim, Adetola A; Baljevic, Muhamed

Ex Vivo Treatment Response Prediction in Multiple Myeloma: Assay Formats, Clinical Correlation, and Future Directions

多发性骨髓瘤体外治疗反应预测:检测方法、临床相关性及未来方向

Oliver, Gavin R; Barnett, Carlton C; Hightower, Kendra E; Kang, Yubin; Baljevic, Muhamed

Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial

axicabtagene ciloleucel 在门诊环境下的可行性:前瞻性试验的初步分析

Dholaria, Bhagirathbhai; Bhaskar, Shakthi T; Patel, Vivek G; Biltibo, Eden; Jayani, Reena; Sengsayadeth, Salyka; Jallouk, Andrew; Jerkins, James; Baer, Brittney; Nur, Ali; Baljevic, Muhamed; Savani, Bipin N; Morgan, David; Kassim, Adetola A; Oluwole, Olalekan O

Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy

塞利尼索在多发性骨髓瘤中的低剂量和每周给药方案——安全性和有效性的最新证据

Baljevic, Muhamed; Schiller, Gary; Mark, Tomer M; Van Domelen, Dane R; Gasparetto, Cristina

Focusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma

重点关注塞利尼索在复发/难治性多发性骨髓瘤CAR-T治疗前的维持和桥接治疗中的应用

Khouri, Jack; Sborov, Douglas; Rossi, Adriana; Martin, Thomas; Kashyap, Trinayan; Mark, Tomer; Baljevic, Muhamed

Long term responders in frontline multiple myeloma-exception vs expectation of the modern era

一线多发性骨髓瘤长期缓解者——现代医学的例外与预期

Baljevic, Muhamed; Sborov, Douglas W; Kumar, Shaji K

Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepository

血管中的克隆性造血和炎症:CHIVE,一项前瞻性、纵向的克隆性造血队列和生物库

Morgan L Shannon, J Brett Heimlich, Sydney Olson, Ariana Debevec, Zachary Copeland, Ashwin Kishtagari, Caitlyn Vlasschaert, Christina Snider, Alexander J Silver, Donovan Brown, Travis Spaulding, Manasa Bhatta, Kelly Pugh, Shannon S Stockton, Jessica Ulloa, Yaomin Xu, Muhamed Baljevic, Javid Moslehi,

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

每周一次服用塞利尼索40毫克与60毫克联合泊马度胺和地塞米松治疗复发和/或难治性多发性骨髓瘤的疗效和安全性比较

White, Darrell; Schiller, Gary J; Madan, Sumit; Lentzsch, Suzanne; Chubar, Evgeni; Lavi, Noa; Van Domelen, Dane R; Bentur, Ohad S; Baljevic, Muhamed

Real-world practitioner perceptions of CARTITUDE-4 results for patients with previously treated multiple myeloma

临床医生对既往接受过治疗的多发性骨髓瘤患者 CARTITUDE-4 结果的真实看法

Balanean, Alexandrina; Baird, Samuel; Dulka, Brooke; Jennings-Zhang, Luke; Bone, Robert N; Jeune-Smith, Yolaine; Feinberg, Bruce; Baljevic, Muhamed